Researchers from Antimicrobial Resistance (AMR) collaborating with researchers from the Massachusetts Institute of Technology (MIT), and also with local institutions such as the Singapore General Hospital, Duke-NUS and Tysana Pte Ltd have developed an antibody treatment for yellow fever, TY014, within only seven months using a Rapid Response Strategy.
The researchers describe the methods and results of Phase 1 of the first-in-human TY014 study in the paper “Phase 1 Trial of a Therapeutic Anti-Yellow Fever Virus Human Antibody” published in the New England Journal of Medicine. The aforementioned study demonstrated the potential treatment using TY014 for yellow fever, a fully engineered, human manufactured IgG1 monoclonal antibody that targets the yellow fever virus, with success in early-stage clinical trials in Singapore.
The paper also details that the condensed timeline for developing TY014, seven months for something that usually takes several years, was facilitated by a development process that carefully monitored product quality and was correlated with safety toxicology and pharmacokinetic studies using redundant orthogonal analytics, performing many of the steps necessary for drug development in parallel.
(Sources: Singapore-MIT Alliance for Research and Technology; BioSpectrum Asia)
